1115 (1115) Fair Value & Analysis

Consumer Defensive · Market cap HK$2.2B

1 1115 1115 · HK

PriceHK$0.4050

Fair ValueHK$0.2600

Upside-35.8%

Quality56/100

Evidence: High Range HK$0.1800 – HK$0.3500

Fair value as of: Jul 2, 2026

From 22 valuation models · updated today

Share price −12.0% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.2750 – HK$0.7200 · fair‑value band HK$0.1800 – HK$0.3500 · the HK$0.4050 price screens above the HK$0.2600 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1115 (1115) currently trades at HK$0.4050, while our model-based Fair Value estimate is HK$0.2600 — implying the stock looks roughly 35.8% overvalued today. We read business quality at 56/100 (solid quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 1115 generated revenue of HK$358M at a net margin of 24.1%. Revenue grew 117.7% year over year. It earns a return on equity of 3.3%. Net debt stands at HK$562M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$358M

Revenue growth (YoY) +118%

Net margin 24.1%

Return on equity 3.3%

Free cash flow HK$87.5M FY2025

P/E ratio 20.3

More key figures

Operating margin 21.2%

EPS (TTM) HK$0.0100

EPS growth (YoY) +284%

Net debt HK$562M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1115 reported revenue of HK$358M in FY2025 versus HK$456M in FY2021, a compound −5.9%/yr. Reported net income was HK$86.2M in FY2025, compounding +16.4%/yr from FY2021.

Revenue −5.9%/yr

FY21 HK$456M

FY22 HK$312M

FY23 HK$314M

FY24 HK$226M

FY25 HK$358M

Net income +16.4%/yr

FY21 HK$47.0M

FY22 −HK$102M

FY23 −HK$353M

FY24 −HK$574M

FY25 HK$86.2M

Is 1115 fairly valued? → Check now

Similar stocks

6 more Beverages - Brewers stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Ambev S.A ABEV	14,120 ARS	5,678 ARS	-60%
Anheuser-Busch InBev SA BUDFF	$79.94	$74.38	-7%
1NBA 1NBA	€71.18	€60.88	-14%
Fomento Económico Mexicano, S.A. FEMSAUBD	213.28 MXN	269.06 MXN	+26%
Heineken N.V HINKF	$81.75	$69.53	-15%
Constellation Brands, Inc STZ	$143.38	$177.43	+24%

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1115 (1115) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.2600 versus a price of HK$0.4050 — about −36% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 1115?

Our model-based fair value for 1115 is HK$0.2600 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.4050.

What is the quality score of 1115?

1115 has a Quality Score of 56/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1115 (1115)?

1115 reported trailing-twelve-month revenue of about HK$358M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1115?

The net profit margin of 1115 is about 24.1%, meaning it keeps roughly 24.1% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.